SciELO - Scientific Electronic Library Online

 
vol.107 issue1Anaemia: Approach to diagnosisOutbreak of carbapenem-resistant Providencia rettgeri in a tertiary hospital author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • On index processSimilars in Google

Share


SAMJ: South African Medical Journal

On-line version ISSN 2078-5135
Print version ISSN 0256-9574

Abstract

VENTER, W D F et al. Cutting the cost of South African antiretroviral therapy using newer, safer drugs. SAMJ, S. Afr. med. j. [online]. 2017, vol.107, n.1, pp.28-30. ISSN 2078-5135.  http://dx.doi.org/10.7196/samj.2017.v107i1.12058.

Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.

        · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License